

Cloning of the rat and human prostaglandin $F_{2\alpha}$ receptors and the expression of the rat prostaglandin $F_{2\alpha}$ receptor

S. Lake^{a,*}, H. Gullberg^a, J. Wahlqvist^a, A.-M. Sjögren^a, A. Kinhult^a, P. Lind^a,
E. Hellström-Lindahl^a, J. Stjernschantz^b

^aPharmacia BioScience Center, S-112 87 Stockholm, Sweden

^bPharmacia Ophthalmics, Glaucoma Research, S-751 82 Uppsala, Sweden

Received 6 October 1994

Abstract We have cloned the FP receptor from rat corpus luteum and human uterus cDNA libraries, respectively. The coding DNA sequence in the rat cDNA is 1101 bp and is similar to the mouse cDNA coding for a receptor protein of 366 amino acids. The human sequence shows a 5 bp deficiency in the 3' region, truncating the coding sequence to 359 amino acids. Northern blot analysis indicates highest expression in the ovary. Cell lines have been established giving stable expression of the FP receptor. Activation of the cloned FP receptor gave an increase in intracellular calcium, indicating signaling via phospholipase C-mediated phosphoinositide turnover. Using [³H]PGF_{2α}, binding of PGs showed the rank order of fluprostenol > PhXA70 > PGF_{2α} ≈ PhXA85 > PGD₂ > PGE₂.

Key words: Prostanoid receptor; PGF_{2α}; Cloning; Expression; Ligand binding; Northern analysis

1. Introduction

Although the presence of specific prostaglandin receptors has been recognized pharmacologically [1,2], only recently has the cloning of prostaglandin receptors been undertaken. Prostaglandin (PG) receptors are classically defined to be linked to the stimulation of second messengers such as cAMP, IP₃ or intracellular calcium release coupled via a G regulatory protein [10]. The activation of prostaglandin receptors may also result in various other responses, including inhibition of adenylyl cyclase activity, inhibition of phosphatidylinositol turnover and inhibition of Ca²⁺ mobilization [10,11]. The first prostaglandin receptor to be cloned was that of thromboxane A₂ (TP) [3]. Subsequently the receptors for PGE₂, the EP₁, EP₂ and EP₃, have been cloned [3–8]. All cloned prostaglandin receptors have been of the seven-transmembrane type, coupled to guanine nucleotide binding regulatory (G) proteins linked to either adenylyl cyclase or the phospholipase C–inositol triphosphate pathway (GPCR), which are amongst the most studied receptor systems [9]. Recently, distinct PG receptors with identical or similar ligand binding specificity have been identified [12]. Such receptors are the isoforms of the EP₃ receptor [13] which have been shown to activate different second messenger systems [14], and the TP receptor have recently been shown to exist in at least two isoforms [15]. Thus, it seems that different isoforms of PG receptors functionally coupled to different second messenger systems exist. While the TP and EP receptors have been cloned and characterized there has not until recently been information available about the FP receptor [16–18]. However, the receptor ligand PGF_{2α} has well-known biological effects such as luteolysis, contraction of the uterus and bronchoconstriction [19,20], and this PG may play an important role in a variety of physiological events. Induction of luteolysis in corpus luteum has been shown in a variety of species from rat to man [21,22]. Astrocytes have been shown to express FP receptors [23], indicating functions of PGF_{2α} in the central nervous system as well. Agonists and antagonists of FP receptors may be important from a

clinical therapeutic point of view in luteolysis, uterine constriction, and increasing the blood pressure etc. Prostaglandins, especially PGF_{2α} and esters of PGF_{2α}, have also been shown to reduce intraocular pressure [24]. Recently, selective analogues of PGF_{2α}, with a potential use as anti-glaucoma agents, have been identified [25] and may be used to treat glaucoma [26], whereas putative drugs which block FP receptors (antagonists) may be used therapeutically to treat pathological conditions, e.g. in the lungs and uterus. Despite their clinical utility, a problem with several currently available FP agonist drugs is their many side effects. These side effects are predominantly due to a lack of receptor specificity, since several of the FP receptor agonists described interact not only with FP receptors but with other receptors as well [10].

2. Material and methods

2.1. Molecular cloning and sequencing analyses of rat and human FP receptors

In order to clone an FP receptor, the polymerase chain reaction (PCR) method was used to amplify cDNA sequences from a rat corpus luteum cDNA library in the Lambda ZAPII vector (Stratagene, USA). Lambda DNA was prepared as described in [27] and submitted to 45 cycles of PCR amplification in a total reaction volume of 25 μl with 1 μM each of the following degenerated primers from transmembrane regions TM2, 5' ATI I(CT)(CG) (TA)I(TC) (TC)TG GCI ITI ICC GAT 3'; and TM7, 5' C(GT)(AG) AAI AGI AT(AG) TAI ACC CAI GGG TC 3'; and 200 μM dNTPs and 2 U *Taq* DNA polymerase (Perkin Elmer-Cetus). The timing used was 45 s (in the first cycle 3 min) at 95°C, 3 min at 50°C and 3 min at 72°C. The 72°C step was extended with 6 s for each cycle. Individual bands were excised from an agarose gel and were submitted separately to 20 cycles of PCR amplification in a total reaction volume of 20 μl with 100 μM of each of the primers in TM2, 5' ATI I(CT)(CG) (TA)I(TC) (TC)TG GCI ITI ICC GAT 3'; and TM7, 5' C(GT)(AG) AAI AGI AT(AG) TAI ACC CAI GGG TC 3'; 200 μM of dNTPs and 2.5 U *Taq* DNA polymerase, otherwise as in the first PCR reaction. PCR fragments were subsequently cloned into the PCR II vector using the TA cloning kit (Invitrogen) according to the instructions from the manufacturer, transformed into One Shot (Invitrogen) competent cells and the DNA sequenced. One insert was found to exhibit close sequence homology to a related receptor. This insert was used as a probe to screen a rat corpus luteum cDNA library to isolate a full-length clone from the rat corpus luteum cDNA library. Positively hybridizing purified phage clones were expanded in *E. coli*

*Corresponding author. Fax: (46) (8) 618 8262.

XL1-Blue, and the resulting phage stocks were used to prepare cDNA-containing pBluescript plasmids by phagemid excision according to the Stratagene protocol. The 4 phagemids with the longest inserts were analyzed by DNA sequencing methods. We sequenced our cDNA with primers homologous to regions on the M13 multiple cloning site according to Applied Biosystems protocol for their Taq Dye Deoxy Terminator cycle sequencing kit. All sequence analysis were performed on a Applied Biosystem Model 373A DNA sequencing system. The generated primary data was processed on a VAX computer using the sequence analysis programs from Genetics Computer Group Inc., Madison, USA [28]. To obtain a human probe, amplification of 350 ng human genomic DNA was performed in a 50 μ l reaction in 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl₂, 0.1% gelatin, 200 μ M each of dATP, dCTP, dGTP, dTTP, 2.5 U Taq polymerase (Perkin-Elmer) and 3 μ M of the oligonucleotides 5'-CAC GAC TTG CCA GAC GGA GAA C-3' and 5'-TTG TAG AAA CAC CAG GTC CT-3'. An initial denaturation step at 94°C followed by 30 cycles of annealing at 55°C 1 min, extension at 72°C 1 min, denaturation at 94°C 1 min, and finally one cycle of 55°C 1 min, 72°C 10 min. One DNA fragment was obtained and cloned and sequenced as above; a 80% homology to the rat sequence indicated that a fragment of the human *fp* gene had been found. To isolate a full-length cDNA of the human *fp* gene, a human uterus cDNA gt11 library (Clontech) was plated and screened with the human probe. Positive plaque pools were picked and subjected to a primary and a secondary PCR analysis with nested primers. PCR amplification was performed in a 50 μ l reaction volume in 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl₂, 0.01% gelatin and the presence of 200 μ M each of dATP, dCTP, dGTP, 2.5 U of Taq polymerase (Perkin-Elmer) and 30 μ M of primer 5'-CAC GAC TTG CCA GAC GGA GAA C-3' and 5'-CCA GTC TTT GAT GTC TTC TGT G-3' each. Secondary PCR was carried out using 1 μ l of the primary PCR reaction as template under the same conditions but with the primers 5'-CAG TAA TCT TCA TGA CAG TGT GG-3' and 5'-TTG TAG AAA CAC CAG GTC CT-3. Positive plaque pools were subjected to another round of hybridization and PCR amplification until single positive plaques could be discriminated. Extracted lambda DNA was digested with *Eco*RI and the DNA fragments were separated on a 0.8% agarose gel in 1 \times TAE. Three fragments were purified and ligated into pBluescriptSK⁺. Screening of clones containing inserts was performed by restriction enzyme analysis. Positive clones were sequenced as above. PCR amplification of the full-length receptor gene for subsequent cloning into an expression vector was performed using the primers 5'-GTA CGT TCT AGA CTC GAG CCA CCA TGT CCA TGA ACA ATT CCA AAC AG-3' and 5'-ATG CAG GCT TCT AGA TGT CCT ATT AAG CTA GGT GCT TGC-3' under the same conditions as previously described. The resulting 1113 bp fragment was cloned into the PCR II vector according to the instructions from the manufacturer, transformed into One Shot (Invitrogen) competent cells and positive clones were screened by restriction enzyme analysis with *Eco*RI. Insert cDNA from rat and human was ligated into PCR/CMV (Invitrogen) and subsequently sequenced in both directions.

2.2. Transfections

A mutant cell line CHO:DG44 (kindly provided by Dr. L. Chasin, Columbia University) where the dihydrofolate reductase (DHFR) gene is deleted was used for transfection. The cells were routinely grown in a modified F12 medium (Gibco BRL, Paisly, Scotland) supplemented with 5% bovine serum (HyClone Laboratories Inc., USA). Cells were transfected by the CaPO₄ precipitate method [30,31] with the above-mentioned rat and human vector constructs, and co-transfected with the DHFR gene in a ratio of 10:1, respectively. Transformants positive for DHFR were selected in a F12 medium lacking hypoxanthine, glycine, thymidine (Gibco BRL), supplemented with 10% dialyzed fetal bovine serum (HyClone Lab Inc.). Methotrexate (Sigma Chemical Co, USA) was used to amplify the transfected genes.

2.3. Flow cytometry

To find high expressing clones, flow cytometry analysis was performed on rat FP-transfected CHO cells, amplified with 20 nM MTX and 100 nM, respectively. The antibodies used in the analysis were biotinylated rabbit anti-FP carboxy-terminal IgG (Pharmacia Bio-Science). Cells in PBS at a density of 10⁷ cells/ml were incubated at 22°C in a concentration of 13 μ g antibody/ml for 30 min. For detection, fluorescein-conjugated avidin (Molecular Probes A-2662) was used.

Cells stained with avidin only were used as a negative control. Flow cytometry analysis was performed using an EPICS 753 (Coulter Electronics, Hialeah, FL).

2.4. Northern blot analysis

Nylon membranes blotted with 2 μ g poly(A)⁺ RNA from eight different rat tissues (heart, brain, spleen, lung, liver, skeletal muscle and testis) and eight human tissues (spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes (MTN-Blot, Clontech) were used for analysis. The rat blots were probed with a rat *fp* fragment and the human blot with a human *fp* fragment according to the protocol for QUIKHYB (Stratagene) and analyzed in a PhosphorImager (Molecular Dynamics).

2.5. Ligand binding

All steps were carried out at +4°C. Cells were washed once with PBS and then scraped from roller bottles into cold PBS and spun down. The cells were homogenized using a glass homogeniser (Dounce) and centrifuged. The supernatant was then centrifuged at 100,000 \times g for 60 min using a Beckman ultracentrifuge, and the final pellet was suspended in 50 mM Tris-HCl, pH 7.0, with 2.5 mM MnCl₂. Protein concentration was determined by the method of Lowry [32]. Cell membranes (100 μ g) were incubated with [³H]PGF_{2 α} (specific activity 154 Ci/mmol; New England Nuclear) in 50 mM Tris-HCl, pH 5.8, containing 2.5 mM MnCl₂ in a total volume of 0.2 ml for 60 min at room temperature. After incubation the samples were filtered through GF filters (particle retention size of 1.0 μ m) using a Skatron cell harvester. Specific binding was calculated by subtracting the values for non-specific binding in the presence of 10⁻⁵ M unlabelled PGF_{2 α} . All samples were assayed in triplicate. In saturation analysis ('hot' Scatchard plot) concentrations of 0.5–15 nM of [³H]PGF_{2 α} were used. For competitive binding, cell membranes were incubated with 3 nM [³H]PGF_{2 α} together with varying concentrations (5 \times 10⁻¹³ to 10⁻⁵ M) of different unlabelled ligands (prostaglandins F_{2 α} , E₂, D₂, fluprostenol, PhXA70 (17-phenyl-18,19,20-trinor-PGF_{2 α}) and PhXA85 (13,14-dihydro-17-phenyl-18,19,20-trinor-PGF_{2 α}) [25]). Ligand binding experiments with CHO cells expressing the human FP receptor were carried out with intact cells cultured in 96-well plates at a density of 10,000 cells/well, incubated with [³H]PGF_{2 α} (0.5–10 nM) in 50 mM Tris-HCl, pH 5.8, containing 2.5 mM MnCl₂ in a total volume of 0.2 ml for 45 min at room temperature. The cells were lysed by adding NaOH to each well and the lysed cells were transferred to scintillation vials, mixed with scintillation cocktail (Ultima Gold; Packard) and counted. Non-specific binding was determined in the presence of 10⁻⁵ M unlabelled PGF_{2 α} . Data were analyzed using the EBDA/LIGAND program [33]. Data were fitted to single and multiple site models and compared for statistically significant differences. The high and low affinity binding sites were designated as R_H and R_L and their corresponding affinity constants as K_H and K_L, respectively. The concentration (IC₅₀) of each ligand to cause 50% inhibition of the binding of [³H]PGF_{2 α} was derived from binding curves. EBDA was used to perform Scatchard analysis for determination of maximum number of binding sites (B_{max}) and dissociation constant (K_d) for [³H]PGF_{2 α} .

2.6. Functional analysis

An analysis of the functional activation of the cellular signal transduction was performed as an activation of intracellular calcium responses in a spectrofluorometer (PTI, USA; data not shown). cAMP analysis gave, as expected, no altered levels in PGF_{2 α} -challenged cells. The functionality was tested in a microphysiometer as well (Cytosensor; Molecular Devices, USA). Activation of second messenger systems have been shown to change the extracellular pH around cells due to an increased metabolism [34].

3. Results and discussion

3.1. Isolation and characterization of full-length cDNA clones for a F_{2 α} receptor: cloning and sequencing analyses of F_{2 α} receptor cDNA

In order to clone the FP receptor, a PCR method was used to selectively amplify cDNA sequences from a rat corpus luteum cDNA library. Ovine and bovine corpus luteum has

was found to exhibit considerable sequence homology to the previously cloned G protein-coupled TP receptor and was subsequently used to screen the rat corpus luteum cDNA library in order to isolate a full-length clone. Twenty-four cDNA clones with insert sizes ranging from about 1.7 to 3.3 kb were isolated, all of which strongly hybridized with the ³²P-labeled PCR probe on southern analysis (data not shown). One of these clones, with an insert of about 3 kb, was sequenced and found to exhibit more than 55% amino acid sequence homology to

The amplified cDNA fragments were preliminarily characterized by DNA sequence analysis. One of the cDNA fragments

[illegible]

Fig. 1. The nucleotide sequence of a FP receptor along with the deduced amino acid sequence of the longest open reading frame. The nucleotide sequence is numbered from the putative initiator methionine and indicated at the left of each line, while the amino acid numbers are indicated at the right of each line. Transmembrane regions are indicated by heavy lines, intracellular regions are in italics and extracellular regions are in normal font. Consensus sites are indicated as follows: *, N-glycosylation; 1, disulphide bond; 2, PKA phosphorylation; 3, PKC phosphorylation; and 4, cysteine myristylation.

```

TATCTCTTGTtCTTtCTTCCctGGGACTCTTAGcTCTCGGcATCTCATTCTCGTGCAAc
601 -----+-----+-----+-----+-----+-----+-----+660
ATAGAGAACAaGAAaaGAAGGGaCCCTGAGAATCgAGAGCCgTAGAGTAAGAGCACGTTg

Y L L F F S S L G L L A L G I S F S C N 220

GcCGtCacGGGAGTCACACTTTTGAGAGTGAAGTTTAGAAGTCAGCAGCACAGGCAAGGC
661 -----+-----+-----+-----+-----+-----+-----+720
CgGCaGTgCCCTCAGTGTGAAAACtCTCACTTCAAATCTTCAGTCGTCGTGTCCGTCCG

A V T G V T L L R V K F R S Q Q H R Q G 240
      IC-3
AGGTCCCACCACCTGGAGATGGTCATTCAGCTCCTGGCCATAATGTGTGTCTCCTGCGTC
721 -----+-----+-----+-----+-----+-----+-----+780
TCCAGGTGGTGGACCTTACCAGTAAGTCGAGGACCGGTATTACACACAGAGGACGCAG

R S H H L E M V I O L L A I M C V S C V 260
      TM-6
TGCTGGAGTCCCTTTCTGGTGACGATGGCCAACATTGCAATCAATGGAAATAATCCCCA
781 -----+-----+-----+-----+-----+-----+-----+840
ACGACCTCAGGGAAAGACCACTGCTACCGGTGTAACGTTAGTTACCTTTATTAAGGGGT

C W S P F L V T M A N I A I N G N N S P 280
      EC-3
GTGACCTGTGAGACGACGCTCTTTGCTCTCCGAATGGCAACCTGGAACCAGATATTAGAC
841 -----+-----+-----+-----+-----+-----+-----+900
CACTGGACACTCTGCTGCGAGAAACGAGAGGCTTACCGTTGGACCTTGGTCTATAATCTG

V T C E T T L F A L R M A T W N O I L D 300
      1
CCCTGGGTCTACATTCTGCTACGGAAGgCTGTCTTAGGAACCTGTACAAGCTTGCCAGT
901 -----+-----+-----+-----+-----+-----+-----+960
GGGACCCAGATGTAAGACGATGCCTTCcGACAGGAATCCTTGGACATGTTCGAACGGTCA

P W V Y I L L R K A V L R N L Y K L A S 320
      C-terminus
CGCTgCTGTGGAGTGAACATCATCAGCTTGCACATCTGGGAACCTCAGCTCCATCAAGAAT
961 -----+-----+-----+-----+-----+-----+-----+102
GCGAcGACACCTCACTTGTAGTAGTCGAACGTGTAGACCCTTGAGTCGAGGTAGTTCTTA

R C C G V N I I S L H I W E L S S I K N 340
      4 4 3
TCCTTAAAGGTTGCTGCTATCTCTGAGTCACCGGCTGCAGAGAAGGAGAATCAgCAAGCA
1021 -----+-----+-----+-----+-----+-----+-----+108
AGGAATTTCCAACGACGATAGAGACTCAGTGGCCGACGTCTCTTCTCTTAGTcGTTCTGT

S L K V A A I S E S P A A E K E N Q Q A 360
      3
TCTAGTGAGGcTGGACTGTAA
1081 -----+-----+-----+-----+-----+-----+-----+1101
AGATCACTCCgACCTGACATT

S S E A G L * 366

```

Fig. 1. (continued).

related PG receptors in the coding regions of the sequence. The nucleotide and deduced amino acid sequence for the cloned FP receptor is shown in Fig. 1. The longest open reading frame in this cDNA codes for a 366 residue protein with a theoretical molecular weight of 41 kDa. Putative glycosylation as well as other post-translational modifications may increase the molecular weight. Although there are neighboring sequences with ATG in the reading frame similar to Kozak's consensus initiation sequence [37], the Met codon at position 1 provides the most probable initiation site (Fig. 1). A Kyte and Doolittle hydrophobicity analysis of the translated protein reveals seven clusters of about 25 hydrophobic residues, predicted to represent transmembrane-spanning domains, connected by three extracellular and three intracellular loops. This pattern is similar to that observed for other cloned G protein-coupled receptors where the amino-terminus is proposed to be extracellular and the carboxy-terminus projects into the cytoplasm [38].

The human FP receptor cDNA was identified and cloned from a human uterus cDNA library using a human probe

obtained with rat-specific PCR primers. Homology analysis showed homology with the published sequence for the human FP receptor [17] except in positions 63 and 213 where cytosine to thymidine substitutions were shown. However, these base substitutions do not give rise to any amino acid substitutions. Comparison between mouse and rat FP cDNA sequences show 83.5% and 80.5% homology, respectively (Table 1). It is interesting to note a 5 bp deletion in the 3' end of the human sequence compared to the mouse and rat sequences, giving a

Table 1
Percent identity and similarity between the FP receptor in man, rat and mouse.

	Rat		Human
Mouse	Id	95.6%	86.7%
	Sim	97.5%	93.6%
Rat			85.6%
			93.1%

Mus	1	MSMNSSKQPVSPAAGLIANTTCQTENRLSVFFSIIFMTVGILSNLAIAI	50
		. : . :	
Hum	1	MSMNSSKQLVSPAXALLSNTTCQTENRLSVFFSVIFMTVGILSNLAIAI	50
		: . . . : . :	
Rat	1	MSINSSKQPASSAAGLIANTTCQTENRLSVFFSIIFMTVGIVSNLAIAI	50
		TM1-----	
Mus	51	LMKAYQRFQKSKASFLLLASGLVITDFFGHLINGGIAVFVYASDKDWIR	100
		. : . :	
Hum	51	LMKAYQRFQKSKASFLLLASGLVITDFFGHLINGAIAVFVYASDKEWIR	100
		. : . :	
Rat	51	LMKAYQRFRRKSKASFLLLASGLVITDFFGHLINGGIAVFVYASDKDWIR	100
		----- TM2-----	
Mus	101	FDQSNILCSILGISMVFSGLCPLFLGSAMAIERCIGVTNPIFHSTKITSK	150
		. : . :	
Hum	101	FDQSNVLCSIFGICMVFSGLCPLLLGSVMAIERCIGVTKPIFHSTKITSK	150
		. : . :	
Rat	101	FDQSNILCSVFGISMVFSGLCPLFLGSTMAIERCIGVTNPLFHSTKITSK	150
		TM3-----	
Mus	151	HVKMILSGVCMFAVFVAVLPILGHRDYQIQASRTWCFYNTEHIEDWEDRF	200
		. : . :	
Hum	151	HVKMMLSGVCLFAVFIALLPILGHRDYKIQASRTWCFYNTEIDKDWEDRF	200
		. : . :	
Rat	151	HVKMILSGVCMFAVFVALLPILGHRDYQIQASRTWCFYNTEHIEDWEDRF	200
		TM4----- TM	
Mus	201	YLLFFSFLGLLALGVSFSCNAVTVTLRLVKFRSQQHRQGRSHHLEMIQ	250
		. : . :	
Hum	201	YLLFFSFLGLLALGVSLCNAITGITLLRVKFKSQQHRQGRSHHLEMIQ	250
		. : . :	
Rat	201	YLLFFSFLGLLALGISFSCNAVTVTLRLVKFRSQQHRQGRSHHLEMIQ	250
		5----- T	
Mus	251	LLAIMCVSCVCWSPFLVTMANIAINGNNSPVTCTTLFALRMAMWNQILD	300
		. : . :	
Hum	251	LLAIMCVSCIWWSPPFLVTMANIGINGNHSLETCETTLFALRMATWNQILD	300
		. : . :	
Rat	251	LLAIMCVSCVCWSPFLVTMANIAINGNNSPVTCTTLFALRMATWNQILD	300
		M6----- TM7-----	
Mus	301	PWVYILLRKAVLRNLYKLASRCCGVNIISLHIWELSSIKNSLKVAATSES	350
		. : . :	
Hum	301	PWVYILLRKAVLRNLYKLASQCCGVHVISLHIWELSSIKNSLKVAATSES	350
		. : . :	
Rat	301	PWVYILLRKAVLRNLYKLASRCCGVNIISLHIWELSSIKNSLKVAATSES	350

Mus	351	PAAEKESQQASSEAGL	366
		. .	
Hum	351	PVAEKSAST.....	359
		. .	
Rat	351	PAAEKENQQASSEAGL	366

Fig. 2. Comparison between the FP receptor amino acid sequences in mouse, man and rat.

translational frame shift and truncating the carboxy-terminus in the human amino acid sequence (Fig. 2).

3.2. Characterization of the amino acid sequences for the rat FP receptor clone

Comparison of the deduced amino acid sequence for the cDNA clones with the sequences of various rodent prostaglandin receptors is shown in Fig. 3. As can be seen, the regions of highest identity appear to occur within the predicted transmembrane-spanning domains. Within these regions, the FP protein exhibits the highest sequence homologies with the mouse EP₁ and TP receptor. The amino- and carboxy-termini and the extracellular and intracellular loops are significantly more divergent among these receptors.

The long carboxy-terminus contains several serine residues, possibly representing additional sites for regulatory phosphorylation. The amino acid sequence reveals, by a theoretical analysis, the following: two possible N-glycosylation sites are

located in the amino-terminus and one in the third extracellular (EC) loop. Four cysteines are located in the putative extracellular parts, giving the possibility for two disulfide bonds. Except for the Cys–Cys bond found in most, if not all, GPCR, in EC-1 and EC-2, FP also has another possible pair in the amino-terminus and the EC-3, a feature shared by the EP₃ but not other PG receptors. Other GPCR's having similar located cysteines seem to belong to the small peptide-ligand receptor family, e.g. the IL-8 receptor.

Consensus recognition sites for phosphorylation of protein kinases of both the PKC and PKA type are found in the intracellular (IC) loops and the carboxy-terminus; all together there are seven Ser and Thr residues as possible sites. These phosphorylations are proposed for the regulation of transmembrane signaling and desensitization of the receptor [39]. Probable Cys myristylation site(s) are located in the carboxy-terminus. EP₃ and EP₂ also have Cys in similar positions. These myristylations give a fourth intracellular loop which may in-

	1				50
RatfpMS	INSSKQPASS	AAGLIANTTC	...QTENRLS	
Musep31MASMWAPEH	SAEAHSNLSS	.TTDDCGSVS	
Mustxa2pMWPNGSTLG	PCFRPVNIT	.LQERRIAS	
Musep1MSPCCGLN	LSLADEAATC	ATPRLPNTSV	VLPDGDNGTS
Musep2MAEVG	GTIPRSNREL	QRCVLLTTTI	MSIPGVNASF	SSTPERLNPS
	51				100
Ratfp	VFFSIIFMTV	GIVSNLSLAIA	ILMKAYQRF	.RKSKASFL	LASGLVITDF
Musep31	VAFPIITMMVT	GFVGNALAML	LVRSYRR.R	ESKRKKSFL	CIGWLALTDL
Mustxa2p	PWFASFAL	GLGSNLLALS	VLGARPGAG	.PRS..SFLA	LLCGLVLTDF
Musep1	PALPIFSMTL	GAVSNVLALA	LLAQVAGMR	RRRSAATFSL	FVASLLAIDL
Musep2	VTIPAVMFIF	GVVGNLVAIV	VLCKSR....	KEQKETTFYT	LVCGLAVTDL
	-----	-----	-----	-----	-----
	101				150
Ratfp	FGHLINGGIA	VFFVYASDKDW	IRFDQSNILC	SVFGISMVFS	GLCPFLFGST
Musep31	VGQLLTSPVV	ILVYLSQRRW	EQLDPGRLC	TFGLTMTVF	GLSSLLVASA
Mustxa2p	LGLLVGTGAIV	ASQHAALLDW	RATDPGCRIC	YFMGVAMVFF	GLCPPLLGA
Musep1	AGHVIPGALV	LRLYTAGR..	..APAGGAC	HFLGGCMVFF	GLCPPLLGC
Musep2	LGTLLVSPVT	IATYMKG.QW	.PGDQ..ALC	DYSTFTLLFF	GLSGLSIICA
	2-----	-----	-----	-----	-----
	151				200
Ratfp	MAIERCIGVT	NPLFHSTKIT	SKHVKMILSG	VCMFAVFVAL	LPILGHRDYQ
Musep31	MAVERALAIR	APHWYASHMK	.TRATPVLLG	VWLSVLAFAL	LPVLGVGRYS
Mustxa2p	MASERFVGIT	RPFSRPTATS	.RRAWATVGL	VWVAAGALGL	LPLLGLGRYT
Musep1	MAVERCVGVT	QPLIHAARVS	VARARLALAV	LAAMALAV	LPLVHVGRYE
Musep2	MSIERYLAIN	HAYFYSHYVD	KRLAGLTIFA	IYASNVLFCA	LPNMGLGRSE
	-----	-----	-----	-----	-----
	201				250
Ratfp	IQASRTWCYF	NTEHIE....	...DWEDRFY	LLFFSSLGLL	ALGISFSCNA
Musep31	VQWPGTWCFI	STGPAGNETD	PAREPGSVAF	ASAFACGLL	ALVVTFCNL
Mustxa2p	VQYPGSWCFL	TLGT.....	...QRGDVVF	GLIFALLGSA	SVGLSLLNL
Musep1	LQYPGTWCFI	SLGPRG....	...GWRQALL	AGLFAGLGLA	ALLAALVCNT
Musep2	RQYPGTWCFI	DWTTTVTAY.AAF	SYMYAGFSSS	LILATVLCNV
	-----	-----	-----	-----	-----
	251				300
Ratfp	VTGVTLL.RV	KFRSQQHRQG	R.....
Musep31	ATIKALVSR	RAKAAVSQSS	AQWGRI....
Mustxa2p	VSVATLC.RV	YHTREATQR
Musep1	LSGLALL.RA	RWRRRSRRF	RKTAGPDDR	RWGSRGPRLA	SASSASSI..
Musep2	LVCGALL.RM	HRQFMR....	RTSLGTEQHH	AAAAAASV	ACRGHAGA..
	---	---	---	---	---
	301				350
Ratfp	SHHLEMVIQL	LAIMCVSCVC	WSPFLVTMA.
Musep31TTETAIQL	MGIMCVLSVC	WSPLLIMMLK
Mustxa2pPR	DCEVEMMVQL	VGIMVVASVC	WMPLLVFMQ
Musep1	TSATATLRSS	RGGGSARRVH	AHDVEMVQQL	VGIMVVCIC	WSPLLVLVVL
Musep2	SPALQRLSDF	RRRRSFRIA	GAEIQMVILL	IATSLVLIC	SIPLVVRVFI
	-----	-----	-----	-----	-----
	351				400
Ratfp	NIA.....	INGNNSPVTC	.ETTLFALRM	ATWNQILDWP	VYILLRKA
Musep31	MIFNOMSVEQ	CKTQMGKEKE	CNSFLIAVRL	ASLNQILDWP	VYILLRKA
Mustxa2p	TLLQTPPVMS	FSGQLLRATE	.HQLLIYLRV	ATWNQILDWP	VYILFRSRV
Musep1	AIG.....G	WNSNSLQ...	.RPLFLAVRL	ASWNQILDWP	VYILLRQAM
Musep2	NQLYQPNVV.KDIS	RNPDLQAIRI	ASVNPILDWP	IYILLRKTVL
	-----	-----	-----	-----	-----
	401				450
Ratfp	RNLYKLASRC	CGVNIISLHI	WELSSIKNSL	KVAASIESPA	AEKENQQASS
Musep31	RKFCQIRDHT	NYASSSTSLP	CPGSSALMWS	DQLER*....
Mustxa2p	RRLHPRFSSQ	LQAVSLRRPP	AQAMLSGP*
Musep1	RQLRLRLPLR	VSAKGGPTEL	GLTKSAWEAS	SLRSSRHSGF	SHL*.....
Musep2	SKAIEKIKCL	FCRIGGSGRD	SSAQHCSES	RTSSAMSGHS	RSFLARELKE
	-----	-----	-----	-----	-----
	451				500
Ratfp	EAGL*....
Musep31
Mustxa2p
Musep1
Musep2	ISSTSQTLLY	LPDLTESSLG	GRNLLPGSHG	MGLTQADTTS	LRTLRISETS
	-----	-----	-----	-----	-----
	501				548
Ratfp
Musep31
Mustxa2p
Musep1
Musep2	DSSQGQDSES	VLLVDEVSGS	HREEPASKGN	SLQVTFPSET	LKLSEKCI*

Fig. 3. Comparison of the rat FP receptor amino acid sequence with that of other known prostaglandin receptors. Amino acid sequences of the mouse TP receptor, the mouse EP₁, EP₂, and EP₃ receptor were aligned to optimize the homology with a rat FP receptor sequence. The putative transmembrane (TM) regions are indicated by the intermittent lines.

teract with G proteins [40] and affect the phosphorylation of the carboxy-terminus [41]. A major difference in size of the third IC loop is observed between FP (together with the EP₃

and TP) and EP₁ and EP₂. The C-terminus of the EP₂ is considerably longer than that of the FP and of the rest of the PG receptors.




Fig. 4. Northern blot, rat. Lane 1, heart; 2, brain; 3, spleen; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, testis. The lower diagram shows a densitometric analysis of the 6 kb band and the relative expression of it in the presented tissues.

The similarity between FP and any PG receptor in the TM regions vary from about 45% in TM4 and TM5 to 76% in TM6 and TM7, the identity, i.e. the same aa in the same position vary from 4% in TM5 to 44% in TM7. The 16 aa most adjacent to the cytoplasm in TM7 are almost all identical, 10/16, an outstanding hallmark of the PG receptors. As pointed out by Hirata earlier [3], the Arg in TM7, conserved in all prostanoid receptors, may reflect the binding site of the acidic group in substances such as the prostaglandins [3,42,43]. It is interesting to note that within the third putative transmembrane domain of FP, as well as in the other PG receptors, there is not a conserved aspartate residue which is common to all biogenic amine receptors that have been sequenced thus far. Moreover, the fifth transmembrane-spanning domain of FP also contains two serine residues conserved among catecholamine receptors and critical for the recognition of agonist ligands possessing a catechol group [44]. Other PG receptors except EP₂ lacks these serines.

3.3. Northern analysis

A common transcript at about 6 kb was shown in all rat tissue (Fig. 4). Heart, brain and skeletal muscle showed additional transcripts of lower size, ranging from 2 to 6 kb. Highest expression was found in brain followed by lung and skeletal muscle. Heart, spleen, liver and testis all expressed the transcript while the kidney showed no detectable expression. The pattern in brain and skeletal muscle were similar. The variation of expression pattern, as shown in our rat tissue blot, differs

Table 2
[³H]PGF_{2α} and [³H]PhXA85 saturation binding characteristics in membrane preparations of CHO cells expressing the transfected rat FP receptor.

Ligand	K _d (nM)	B _{max} (fmol/mg protein)
PGF _{2α}	8.3 ± 2.5	78 ± 23
PhXA85	18.5 ± 0.1	158 ± 18

Data are mean ± SE of 3 independent experiments

from previously published thromboxane and prostaglandin E receptors both in the size of transcript and the multiplicity of transcripts in the tissues of heart, brain and muscle. The possibility that subtypes of the FP receptor exist can not be ruled out since a cross-hybridization with other PG receptors seem unlikely according to the published sizes of major PG receptor transcripts in mice. A study of the various sized bands in rat tissues has currently started. The human tissues examined did not show the size variability in transcripts found in rat (Fig. 5). A major transcript of about 6 kb was found in all tissues expressing the FP receptor, with the highest expression in the ovary followed by the small intestine, prostate, spleen and testis. Weak expression was shown in the colon and thymus but no expression was detectable in leukocytes. In tissues with a high expression, a minor transcript of a larger size of 6.5 kb could be detected. These different mRNA expression data may indicate a species difference in putative subtypes of the FP receptor.

3.4. Ligand binding

Ligand binding with radiolabeled [³H]PGF_{2α} and competition with other prostaglandins on membranes prepared from the transfected cells is one way of confirming the identity of the cloned cDNA. Scatchard analysis showed a specific [³H]PGF_{2α} binding to these membranes with a K_d value of 8.3 ± 2.5 nM




Fig. 5. Northern blot, human. Lane 1, spleen; 2, thymus; 3, prostate; 4, testis; 5, ovary; 6, small intestine; 7, colon; 8, leukocyte. Otherwise as Fig 4.




Fig. 6. Microphysiometer analysis of CHO cells expressing the transfected rat FP receptor (series 2) and untransfected CHO cells (series 1). Prostaglandins D_2 and $F_{2\alpha}$ are tested in this experiment by challenging the cells in the two treatment periods, respectively. % change in $-\mu V/s$ on the x-axis and time in seconds after the start of the microphysiometer on the y-axis.

and a B_{max} of 78 ± 23 fmol/mg protein (Table 2). The rank order of potency of prostaglandins competing for [3H]PGF $_{2\alpha}$ -specific binding at the FP receptor was fluprostenol > PhXA70 > PGF $_{2\alpha}$ \geq PhXA85 > PGD $_2$ > PGE $_2$ (Table 3). A two-site model gave the best fit with the two ligands PGF $_{2\alpha}$ and fluprostenol; PhXA85 and the other gave best fit with a one-site model (for K_i , IC_{50} and B_{max} values see Table 4). These values are in agreement with published values of tissue preparations expressing the FP receptor. Comparing these ligand binding data with the ones presented for the cloned mouse and human FP receptors [16,17], there is a difference in the binding of PGD $_2$ to the rat and mouse FP receptor compared to the human receptor. The binding of PGD $_2$ and PGF $_{2\alpha}$ to the human FP receptor does not differ significantly, while in the rat and mouse there is a difference in binding of 10–100 times between PGD $_2$ and PGF $_{2\alpha}$.

Untransfected CHO cells as well as FP receptor transfected cells were stimulated with prostaglandins. The PGF $_{2\alpha}$ stimulations gave alterations in pH around the transfected CHO cells but not in the untransfected host CHO cells. Stimulations with PGD $_2$ gave no response in any of the two cell lines (Fig. 6). The functional analysis of the FP receptor-expressing CHO cells showed a coupling to PLC and an activation of intracellular calcium as expected (data not shown). It was also possible to analyze physiological responses when challenging the stable

FP-expressing CHO cell line with various PGs (Fig. 6). These observations suggest that our rat cDNA clone encodes an endogenous prostaglandin $F_{2\alpha}$ receptor and that we have a functional response in our transfected rat FP-expressing CHO cells.

A major goal of clinical pharmacology and the pharmaceutical industry is the development of more selective drugs with greater efficacy than those currently in use. Impediments for such a process regarding targeting of the FP receptor are the low abundance of the receptor protein available to study in tissue, and the lack of suitable homogeneous model systems of the receptors with which to screen drugs. Commonly cells used for PGF $_{2\alpha}$ receptor analysis are obtained from bovine corpus luteum preparations, which also contain EP receptors [35].

A novel approach to the solution of this problem is to clone cDNAs encoding FP receptors, construct expression vectors containing these cDNAs, and create a series of stable transfected mammalian cell lines or prokaryotic cells which express functional FP receptors in abundance. These cell lines, which would express a homogeneous population of FP receptors, can be used by the pharmaceutical industry or others to screen drugs and study the FP receptors using a variety of biochemical, physiological and pharmacological techniques. To accomplish this goal, we have isolated the cDNA encoding a rat FP receptor linked to the activation of second messengers as measured by intracellular calcium. This cDNA was inserted

Table 3
Binding parameters of prostanoid agonists to membranes prepared from CHO cells expressing the transfected rat FP receptor.

Ligand	K_i (nM)	IC_{50} (nM)	B_{max} (fmol/mg)	Two site model*			
				K_H (nM)	K_L (nM)	R_H (%)	R_L (%)
PGF $_{2\alpha}$	11 ± 2	18 ± 3	146 ± 4	3.9 ± 1.6	34 ± 10	55 ± 8	45 ± 8
PGE $_2$	400 ± 100	660 ± 170	153 ± 8				
PGD $_2$	470 ± 170	800 ± 254	184 ± 18				
PhXA 85	11 ± 2	18 ± 4	136 ± 11				
PhXA 70	1.1 ± 0.2	1.7 ± 0.3	48 ± 2				
Fluprostenol	0.4 ± 0.1	7.5 ± 1.5	114 ± 3	0.2 ± 0.9	22 ± 10	65 ± 3	35 ± 3

Data are means \pm SE from 3–4 independent experiments

K_H and K_L = affinity constants for high and low binding sites

R_H and R_L = proportion of high and low affinity binding sites

*The two-site fit is significant better ($P > 0.05$) than the single site analysis

Table 4

K_d values for [3 H]PGF $_{2\alpha}$ specific FP receptor binding to intact CHO cells expressing the rat and human FP receptor, respectively.

Receptor	K_d (nM)	n
Rat	2.25 \pm 0.34	4
Human	1.63 \pm 0.39	3

mean values \pm SE

into different eukaryotic expression vectors and used in the construction of cell lines expressing a functional protein. The resulting FP receptor-expressing cell lines were used to investigate the affinity and efficacies of agonist and putative antagonist drugs of a FP receptor using various techniques, such as radioligand binding and in mammalian cell line second messenger assays.

Acknowledgements: We thank P. Denker, J. Dixelius, S.-Å. Franze'n, M. Israelsson, K. Krook, and S. Lillebo for skillful technical assistance.

References

- [1] Kennedy, I., Coleman, R.A., Humphrey, P.P.A., Levy, G.P. and Lumley, P. (1982) Prostaglandins 24, 667–689.
- [2] Coleman, R.A. and Sheldrick, R.L. (1989) Br. J. Pharmacol. 96, 688–92.
- [3] Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S. and Narumiya, S. (1991) Nature 349, 617–20.
- [4] Sugimoto, Y., Namba, T., Honda, A., Hayashi, Y., Negishi, M., Ichikawa, A. and Narumiya, S. (1992) J. Biol. Chem. 267, 6463–6.
- [5] Honda, A., Sugimoto, Y., Namba, T., Watabe, A., Irie, A., Negishi, M., Narumiya, S. and Ichikawa, A. (1993) J. Biol. Chem. 268, 7759–62.
- [6] Watabe, A., Sugimoto, Y., Honda, A., Irie, A., Namba, T., Negishi, M., Ito, S., Narumiya, S. and Ichikawa, A. (1993) J. Biol. Chem. 268, 20175–8.
- [7] Funk, C.D., Furci, L., FitzGerald, G.A., Grygorczyk, R., Rochette, C., Bayne, M.A., Abramovitz, M., Adam, M. and Metters, K.M. (1993) J. Biol. Chem. 268, 26767–72.
- [8] Kunapuli, S.P., Fen-Mao, G., Bastepe, M., Liu-Chen, L.Y., Li, S., Cheung, P.P., DeRiel, J.K. and Ashby, B. (1994) Biochem. J. 298, 263–7.
- [9] Probst, W.C., Snyder, L.A., Schuster, D.I., Brosius, J. and Sealfon, S.C. (1992) DNA Cell Biol. 11, 1–20.
- [10] Muallem, S., Merritt, B.S., Green, J., Kleeman, C.R. and Yamaguchi, D.T. (1989) Biochem. J. 263, 769–774.
- [11] Duncan, R.A. and Davis, J.S. (1991) Endocrinology 128, 1519–1526.
- [12] Balapure, A.K., Caicedo, I.C., Kawada, K., Watt, D.S., Rexroad, C.E. and Fitz, T.A. (1989) Biol. Reproduction 41, 385–392.
- [13] Sugimoto, Y., Negishi, M., Hayashi, Y., Namba, T., Honda, A., Watabe, A., Hirata, M., Narumiya, S. and Ichikawa, A. (1993) J. Biol. Chem. 268, 2712–8.
- [14] Namba, T., Sugimoto, Y., Negishi, M., Irie, A., Ushikubi, F., Kakizuka, A., Ito, S., Ichikawa, A. and Narumiya, S. (1993) Nature 365, 166–70.
- [15] Raychowdhury, M.K., Yukawa, M., Collind, L.J., McGrail, S.H., Kent, K.G. and Ware, J.A. (1994) J. Biol. Chemistry. 269, 19256–19261.
- [16] Sugimoto, Y., Hasumoto, K., Namba, T., Irie, A., Katsuyama, M., Negishi, M., Kakizuka, A., Narumiya, S. and Ichikawa, A. (1994) J. Biol. Chem. 269, 1356–60.
- [17] Abramovitz, M., Boie, Y., Nguyen, T., Rushmore, T.H., Bayne, M.A., Metters, K.M., Slipetz, D.M. and Grygorczyk, R. (1994) J. Biol. Chem. 269, 2632–6.
- [18] Sakamoto, K., Ezashi, T., Miwa, K., Okuda-Ashitaka, E., Houtani, T., Sugimoto, T., Ito, S. and Hayaishi, O. (1994) J. Biol. Chem. 269, 3881–6.
- [19] Horton, E.W. and Poyser, N.L. (1976) Physiol. Rev. 56, 595–651.
- [20] Coleman, R.A. and Kennedy, I. (1985) Prostaglandins 29, 365–75.
- [21] Muller, U., Bauknecht, Th. and Siebers, J.W. (1981) Acta Endocrinologica 98, 441–445.
- [22] Abayasekara, D.R.E., Jones, P.M., Persaud, S.J., Michael, A.E. and Flint, A.P.F. (1993) Mol. Cell. Endocrinol. 91, 51–57.
- [23] Kitanaka, J., Onoe, H. and Baba, A. (1991) Biochem. Biophys. Res. Commun. 178, 946–952.
- [24] Camras, C.B. and Bito, L.Z. (1981) Curr. Eye Res. 1, 205–209.
- [25] Stjernschantz, J. and Resul, B. (1992) Drugs of the Future 17, 691–704.
- [26] Alm, A. and Villumsen, J. (1991) Arch. Ophthalmol. 109, 1564–1568.
- [27] Ausubel, I. and Frederick, M. (1994) Current Protocols in Molecular Biology, Wiley, NY, USA.
- [28] Devereux (1984) Nucleic Acids Res. 12, 387–395.
- [29] Hanahan, D. (1988) Annu. Rev. Genet. 22, 479–519.
- [30] Graham, F.L. and Van der Eb, A.J. (1973) Virology 52, 456–467.
- [31] Wigler, M., Pellicer, A., Silverstein, S., Axel, R., Urlaub, G. and Chasin, L. (1979) Proc. Natl. Acad. Sci. USA 76, 1373–1376.
- [32] Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) J. Biol. Chem. 193, 265–275.
- [33] McPherson, G.A. (1985) J. Pharmacol. Methods 14, 213–228.
- [34] McConnell, H.M., Owicky, J.C., Parce, J.W., Miller, D.L., Baxter, G.T., Wada, H.G. and Pitchford, S. (1992) Science 257, 1906–1912.
- [35] Rao, C.V. (1974) J. Biol. Chem. 249:7203–9.
- [36] Orlicky, D.J., Miller, G.J. and Evans, R.M. (1990) Prostaglandins Leukot. Essent. Fatty Acids 41, 51–61.
- [37] Kozak, M. (1984) Nucleic Acids Res. 12:857–872.
- [38] Dohman, H.G., Caron, M.G. and Lefkowitz, R.J. (1987) Biochemistry 26, 2657–2664.
- [39] Sibley, D.R., Benovic, J.L., Caron, M.G. and Lefkowitz, R.J. (1987) Cell 48, 913–922.
- [40] Strosberg, D. (1993) Protein Sci. 2, 1198–1209.
- [41] Moffett, S., Moillac, B., Bonin, H. and Bovier, M. (1993) EMBO J. 12, 349–356.
- [42] Narumiya, S., Hirata, N., Namba, T., Hayashi, Y., Ushikubi, F., Sugimoto, Y., Negishi, M. and Ichikawa, A. (1993) J. Lipid Mediat. 6, 155–61.
- [43] Yamamoto, Y., Kamiya, K. and Terao, S. (1993) J. Med. Chem. 820–825.
- [44] Strader, C.D., Sigal, I.S. and Dixon, R.A. (1989) FASEB J. 3, 1825–32.